Abstract: PO1921
Lupus-Related Renal Disease Increases Inpatient Mortality: Analysis of the National Inpatient Sample
Session Information
- Glomerular Diseases: Clinical, Outcomes, and Trials - 3
October 22, 2020 | Location: On-Demand
Abstract Time: 10:00 AM - 12:00 PM
Category: Glomerular Diseases
- 1203 Glomerular Diseases: Clinical, Outcomes, and Trials
Authors
- Edigin, Ehizogie, John H Stroger Hospital of Cook County, Chicago, Illinois, United States
- Eseaton, Precious, University of Benin Teaching Hospital, Benin City, Edo, Nigeria
- Manadan, Augustine, Rush University Medical Center, Chicago, Illinois, United States
Background
The aim of this study is to analyze the difference in outcomes of Systemic Lupus Erythematosus (SLE) with and without lupus-related renal disease. The primary outcome was inpatient mortality, while secondary outcomes were hospital length of stay (LOS) and total hospital charges.
Methods
Data were abstracted from the National Inpatient Sample (NIS) 2016 and 2017 Database. NIS is the largest inpatient admission database in the USA. The NIS was searched for adult SLE hospitalizations with and without lupus-related renal disease as principal or secondary diagnosis using ICD-10 codes. Multivariate logistic and linear regression analysis was used to adjust for confounders for the primary and secondary outcomes respectively. STATA software was used to analyze the data.
Results
There were over 71 million discharges included in the combined 2016 and 2017 NIS database. 355,740 hospitalizations were for adult patients, who had either a principal or secondary ICD-10 code for SLE. 51,875 (14.6%) and 303,865 (85.4%) of these hospitalizations were for SLE with and without lupus-related renal disease respectively. 7,060 adult SLE hospitalizations (2%) resulted in inpatient mortality. 1,110 (2.14%) of the deaths occurred in SLE with lupus-related renal disease vs 5950 (1.96%) without lupus-related renal disease (P=0.228). The adjusted odds ratio (AOR) for inpatient mortality for SLE with lupus-related renal disease compared to those without lupus-related renal disease was 1.38 (95% CI 1.17-1.63, P<0.0001). SLE with lupus-related renal disease hospitalizations had a mean increase in adjusted LOS of 1.14 days (95% CI 0.95-1.34, P<0.0001) compared to SLE without lupus-related renal disease. Hospitalizations for SLE with lupus-related renal disease had an increase in adjusted total hospital charges of $15,910 (95% CI 13,085-18,736, P<0.0001) compared to SLE without lupus-related renal disease.
Conclusion
Hospitalizations for SLE with lupus-related renal disease have increased inpatient mortality, LOS, and total hospital charges compared to those without lupus-related renal disease. SLE patients with lupus-related renal disease require a multidisciplinary approach involving the rheumatologist and nephrologist to optimize outcomes.